News

In June of this year, Gilead delivered a notice of termination to Roche of the companies’ 1996 agreement relating to Tamiflu and the companies subsequently entered into arbitration.

Pfizer had been hoping to secure a key marketing advantage for Lipitor but although the trial demonstrated an 11% reduction in major coronary events in Lipitor patients compared

Recent analytical-study results were submitted to the FDA and cleared for incorporation into the analytical sensitivity section of the Xpect Flu A&B package insert. Testing was performed in

Although Thalomid is already prescribed off-label by doctors wishing to treat multiple myeloma (progressive blood cancer), Celgene is intent on acquiring official recognition for the indication. In response

To date, 31 patients have been treated across eight dose levels and are available for safety analysis. In the trial, XL647 was generally well tolerated with fatigue, nausea

The studies were designed to determine whether torcetrapib/Lipitor therapy can effectively raise HDL (‘good’) cholesterol while lowering LDL (‘bad’) cholesterol, a leading risk factor for heart disease. In

European orphan drug designation is designed to encourage companies to develop and market treatments for rare, life-threatening medical conditions that affect fewer than five people in every 10,000

Under the terms of the license agreement, American BioScience will receive upfront and milestone payments in excess of $50 million, in addition to substantial royalties. Abraxane for injectable

The companies originally entered into an agreement in December 2004, under which Johnson & Johnson was to pay $25.4 billion for Guidant. However, product recalls at Guidant and